Minerva Neurosciences Inc (NERV)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $114.62M
Last updated: Nov 17, 2026 at 11:06 AM ET
Minerva Neurosciences Inc (NERV) Financials: Revenue, Profit and Cash Flow
Minerva Neurosciences reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$293.42M, operating cash flow was -$13.51M and free cash flow was -$13.51M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of $100.75M.
Revenue and Margins
The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $15.10M.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $0 | N/A | N/A | N/A | N/A |
| Dec 2024 | $0 | N/A | N/A | N/A | N/A |
| Dec 2023 | $0 | N/A | N/A | N/A | N/A |
| Dec 2022 | $0 | N/A | N/A | N/A | N/A |
| Dec 2021 | $0 | -100.0% | N/A | N/A | N/A |
| Dec 2020 | $41.18M | N/A | 100.0% | 4.5% | 4.7% |
| Dec 2019 | $0 | N/A | N/A | N/A | N/A |
| Dec 2018 | $0 | N/A | N/A | N/A | N/A |
| Dec 2017 | $0 | N/A | N/A | N/A | N/A |
| Dec 2016 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the company posted a net loss after a profit the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $41.18M | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $41.18M | $0 | $0 | $0 | $0 |
| Research and development | $5.76M | $11.90M | $12.71M | $14.65M | $32.04M | $22.04M | $58.12M | $34.89M | $30.26M | $20.44M |
| Operating income | -$15.10M | -$21.85M | -$23.12M | -$25.23M | -$45.37M | $1.85M | -$75.87M | -$51.73M | -$41.17M | -$30.19M |
| Net income | -$293.42M | $1.44M | -$30.01M | -$32.11M | -$49.91M | $1.94M | -$72.18M | -$50.17M | -$31.52M | -$31.05M |
| EBITDA | N/A | $4.75M | -$23.09M | N/A | -$45.30M | $1.87M | -$74.97M | N/A | N/A | -$29.75M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $42.22K | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | -$1.36K | $0 | $0 | $0 | $21.11K | $0 | $0 | $0 | -$7.75K |
| Operating income | -$9.43M | -$10.64M | -$16.67M | -$4.98M | -$2.84M | -$3.37M | -$3.90M | -$4.52M | -$4.37M | -$6.28M | -$6.68M | -$7.17M |
| Net income | $100.75M | $17.47M | -$125.40M | -$283.67M | -$2.74M | -$3.26M | -$3.75M | -$4.27M | $22.51M | -$8.23M | -$8.57M | -$9.02M |
Balance Sheet
As of Dec 2025, cash and equivalents of $82.30M were 84.0% of total assets of $97.97M, against total liabilities of $233.76M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $97.97M | $37.14M | $56.90M | $55.09M | $77.12M | $57.63M | $77.50M | $139.14M | $183.70M | $132.94M |
| Current assets | $83.10M | $22.27M | $42.00M | $40.16M | $62.20M | $27.44M | $47.14M | $90.02M | $129.54M | $83.86M |
| Cash and equivalents | $82.30M | $21.36M | $40.91M | $36.09M | $60.76M | $25.36M | $21.41M | $50.23M | $26.05M | $82.98M |
| Total liabilities | $233.76M | $62.84M | $85.36M | $75.11M | $69.15M | $4.96M | $49.72M | $48.87M | $52.10M | $26.96M |
| Short-term debt | N/A | N/A | N/A | N/A | N/A | $111.23K | $172.90K | $41.18B | $3.96M | $4.85M |
| Long-term debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 | $3.84M |
| Shareholder equity | -$140.75M | -$25.69M | -$28.46M | -$20.02M | $7.98M | $52.66M | $27.78M | $90.26M | $131.60M | $105.98M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $98.28M | $95.09M | $94.03M | $97.97M | $28.09M | $30.42M | $32.80M | $37.14M | $42.81M | $46.29M | $50.51M | $56.90B |
| Total liabilities | $184.06M | $296.65M | $343.08M | $238.72M | $62.67M | $62.53M | $61.95M | $62.84M | $64.48M | $90.78M | $87.10M | $85.36B |
| Cash and equivalents | $20.22M | $24.65M | $32.66M | $82.30M | $12.29M | $15.25M | $17.29M | $21.36M | $26.53M | $30.88M | $34.82M | $40.91B |
| Shareholder equity | -$97.52M | -$213.30M | -$254.01M | -$140.75M | -$34.58M | -$32.11M | -$29.15M | -$25.69M | -$21.67M | -$44.49M | -$36.59M | -$28.46B |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$13.51M | -$19.55M | -$14.78M | -$24.65M | -$24.60M | -$33.82M | -$43.43M | -$41.94M | $3.09M | -$25.69M |
| Capital expenditures | $0 | $0 | $0 | $16.33K | $0 | $16.33K | $3 | $0 | $52.40K | $0 |
| Free cash flow | -$13.51M | -$19.55M | -$14.78M | -$24.66M | -$24.60M | -$33.84M | -$43.43M | -$41.94M | $3.04M | -$25.69M |
| Dividends paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $10.49M | $0 |
| Share repurchases | $5.39M | $0 | $396.29K | $0 | N/A | $455.67K | $0 | N/A | $2.94M | $3.83M |
| Investing cash flow | $0 | $0 | $0 | -$16.33K | $0 | $24.53M | $14.08M | $69.49M | -$107.19M | $17.82M |
| Financing cash flow | $74.45M | $0 | $19.60M | -$5 | $60.00M | $13.24M | $525.00K | -$3.34M | $47.17M | $76.57M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.15M | -$13.34M | -$5.43M | -$4.48M | -$2.92M | -$2.04M | -$4.07M | -$5.17M | -$4.35M | -$3.94M | -$6.09M | -$5.99M |
| Capital expenditures | N/A | N/A | $0 | $0 | $2 | $2 | $0 | $0 | $0 | $0 | $0 | $0 |
| Free cash flow | N/A | N/A | -$5.43M | -$4.48M | -$2.92M | -$2.04M | -$4.07M | -$5.17M | -$4.35M | -$3.94M | -$6.09M | -$5.99M |
Frequently Asked Questions About NERV
What is Minerva Neurosciences' annual revenue?
Minerva Neurosciences reported revenue of $0 for the fiscal year ended Dec 31, 2025.
Is Minerva Neurosciences profitable?
No. Minerva Neurosciences reported net income of -$293.42M for the fiscal year ended Dec 31, 2025.
How much free cash flow does NERV generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$13.51M minus capital expenditures of $0 produced free cash flow of -$13.51M.
How much debt does Minerva Neurosciences have?
The balance sheet dated Dec 31, 2025 reported cash and equivalents of $82.30M.
NERV pages: Overview, Earnings, Forecast, Financials, Competitors